Scarica l'app Stockscreener
54.48
0.85%
0.46
Dopo l'orario di chiusura:
55.00
0.52
+0.95%
Precedente Chiudi:
$54.02
Aprire:
$53.85
Volume 24 ore:
78,415
Relative Volume:
0.37
Capitalizzazione di mercato:
$364.59M
Reddito:
-
Utile/perdita netta:
$-13.72M
Rapporto P/E:
-27.43
EPS:
-1.9861
Flusso di cassa netto:
$-12.20M
1 W Prestazione:
+3.36%
1M Prestazione:
+0.70%
6M Prestazione:
-31.83%
1 anno Prestazione:
+33.50%
Intervallo 1D:
$53.65
$55.42
Intervallo di 1 settimana:
$50.22
$55.42
Portata 52W:
$28.40
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Nome
Monopar Therapeutics Inc
Settore
Industria
Telefono
(847) 388-0349
Indirizzo
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
54.48 | 361.51M | 0 | -13.72M | -12.20M | -1.9861 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-09 | Iniziato | Morgan Stanley | Overweight |
| 2025-11-14 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | Iniziato | Leerink Partners | Outperform |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-09-09 | Iniziato | BTIG Research | Buy |
| 2025-09-03 | Iniziato | Oppenheimer | Outperform |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-08-26 | Ripresa | H.C. Wainwright | Buy |
| 2025-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-23 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-19 | Ripresa | Piper Sandler | Overweight |
| 2025-01-10 | Iniziato | Piper Sandler | Overweight |
| 2024-10-11 | Iniziato | Rodman & Renshaw | Buy |
| 2021-01-28 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Monopar Therapeutics Inc Borsa (MNPR) Ultime notizie
(MNPR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
MNPR (Monopar Therapeutics Inc.) slips 2.56% after Q4 2025 earnings miss on larger than expected per share loss.ROIC - Xã Thanh Hà
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON) - The Globe and Mail
MNPR Stock Price, Quote & Chart | MONOPAR THERAPEUTICS INC (NASDAQ:MNPR) - ChartMill
Monopar Therapeutics stock maintained at Buy by Lake Street on trial data - Investing.com Canada
Monopar Therapeutics stock maintained at Buy by BTIG on trial data - Investing.com Canada
Monopar Reports Phase 3 Data Showing ALXN1840 Provides Greater Neurologic Benefit Versus Standard of Care in Wilson Disease Patients - Minichart
ALXN1840 Poised to Redefine Wilson Disease Treatment Standards: Phase 3 Success, De-Risked Profile, and Buy Rating Justification - TipRanks
Monopar Highlights Strong Phase 3 Data for ALXN1840 - TipRanks
Monopar (MNPR) unveils Phase 3 ALXN1840 neurologic gains and plans mid-2026 NDA - Stock Titan
Lake Street Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation - MSN
Monopar Therapeutics (MNPR) Shows Promising Results in Wilson Di - GuruFocus
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 - The Manila Times
Monopar Therapeutics Reports Positive Phase 3 Trial Results for ALXN1840 in Wilson Disease Patients at AAN Annual Meeting 2026 - Quiver Quantitative
Wilson disease study: 9% worsened on ALXN1840 vs 25% on standard care - Stock Titan
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Monopar Therapeutics (MNPR) Stock Sector Perform (Weakens) 2026-04-16High Volume Stocks - Xã Vĩnh Công
How (MNPR) Movements Inform Risk Allocation Models - Stock Traders Daily
Chardan Capital Reaffirms Buy Rating on MNPR with $100 Price Tar - GuruFocus
Monopar Therapeutics (NASDAQ:MNPR) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
Is Monopar Therapeutics Inc a momentum stock2026 Earnings Surprises & Weekly Top Gainers Trade List - baoquankhu1.vn
Is Monopar Therapeutics Inc stock technically oversold2026 Risk Factors & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Q1 EPS Estimate for Monopar Therapeutics Boosted by Analyst - defenseworld.net
Monopar Therapeutics Inc (MNPR) Gets a Buy from JonesTrading - The Globe and Mail
Brookline Capital Markets Forecasts MNPR Q1 Earnings - MarketBeat
Gains Report: Will Monopar Therapeutics Inc benefit from sector rotationQuarterly Trade Review & Long Hold Capital Preservation Plans - baoquankhu1.vn
Trading Systems Reacting to (MNPR) Volatility - Stock Traders Daily
MNPR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Monopar Therapeutics Inc. (1IY0.SG) stock price, news, quote and history - Yahoo Finance Singapore
Monopar Therapeutics Inc. (1IY0.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
[Form 4] Monopar Therapeutics Insider Trading Activity - Stock Titan
Monopar Therapeutics (MNPR) COO gains shares through RSU vesting and tax withholding - Stock Titan
Monopar Therapeutics Inc. 2025 Annual Report Amendment: Financial Highlights, Corrections, and Key SEC Filings - Minichart
Monopar Therapeutics | 10-K/A: Annual report (Amendment) - Moomoo
Monopar (NASDAQ: MNPR) 10-K/A shows $13.7M loss but strong cash - Stock Titan
HC Wainwright Brokers Reduce Earnings Estimates for MNPR - MarketBeat
Monopar Therapeutics Inc. (1IY0.SG) Analyst Ratings, Estimates & Forecasts - Yahoo! Finance Canada
Monopar Therapeutics Inc (MNPR) Receives a Buy from Lake Street - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
MNPR SEC FilingsMonopar Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
MNPR's Rating Maintains 'Buy' by Chardan Capital: March 30, 2026 - GuruFocus
Chardan Capital Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Monopar Therapeutics stock price target maintained at $104 by BTIG - Investing.com Canada
Monopar Therapeutics Inc. Q4 and Full Year 2025 Earnings: Net Loss Narrows to $13.7M - Bayelsa Watch
Monopar Therapeutics (STU:1IY0) NonCurrent Deferred Revenue : €0.00 Mil (As of Sep. 2025) - gurufocus.com
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update - The Manila Times
Leerink reiterates Monopar stock rating on Wilson disease drug potential By Investing.com - Investing.com Canada
Raymond James reiterates Monopar stock rating on NDA timing shift By Investing.com - Investing.com Canada
Is Flanigans Enterprises Inc stock a hidden gem2026 Big Picture & Detailed Earnings Play Strategies - baoquankhu1.vn
Monopar Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
MNPR: ALXN1840 advances toward NDA in 2026 as financials improve and cash reserves strengthen - TradingView
Monopar Therapeutics Inc Azioni (MNPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.29%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):